

01-14-2004

FORM PTO-1595  
1-31-92

RECC



102645254

U.S. DEPARTMENT OF COMMERCE  
Patent and Trademark

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):  
Mohamed Mohamed Ali Awad, Marc Jacques Bazin,  
Frederic Feru, Steven Wayne Goldstein, Cyrille  
Francois Kuhn

2. Name and address of receiving party(ies):  
Warner-Lambert Company LLC  
201 Tabor Road  
Morris Plains  
New Jersey 07950

Additional name(s) of conveying party(ies) attached?  Yes  No

Additional name(s) & address(es) attached?  Yes  No

3. Nature of conveyance:

Assignment  Merger  
 Security Agreement  Change of Name  
 Other

Execution Date: <sup>1</sup> December 5, 2003  
<sup>2</sup> December 18, 2003  
<sup>3</sup> December 18, 2003

<sup>4</sup> December 9, 2003  
<sup>5</sup> December 10, 2003

4. Application number(s) or patent number(s): **United States Patent Application No. 10/688,566, filed October 17, 2003**

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s) B. Patent No. (s)

Additional numbers attached?  Yes  No

5. Name and address of party to whom  
correspondence concerning document should be  
mailed:

Name: Gregg C. Benson

Internal Address: Pfizer Inc.

Street Address: Eastern Point Road, MS 8260-1611

City: Groton State: Connecticut ZIP: 06340

6. Total number of pages including cover sheet,  
attachments and document:

7. Total fee (37 CFR 3.41).....\$ 40.00

Enclosed

Authorized to be charged to deposit account

8. Deposit account number:

16-1445

(Attach duplicate copy of this page if paying by deposit account)

**DO NOT USE THIS SPACE**

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached document is the original or a true copy of the original document.

Robert T. Ronau  
Name of Person Signing

Robert T. Ronau Signature January 8, 2004 Date

Total number of pages including cover sheet: 3

OMB No. 0651-0011 (exp. 4/94)

**Do not detach this portion**

Mail documents to be recorded with required cover sheet information to:

**Commissioner for Patents**  
**PO Box 1450**  
**Alexandria, VA 22313-1450**

2004

Public burden reporting for this sample cover sheet is estimated to average about 30 minutes per document to be recorded, including time for reviewing the document and gathering the data needed, and completing and reviewing the sample cover sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Office of Information Systems, PK2-1000C, Washington, D.C. 20231, and to the Office of Management and Budget, Paperwork Reduction Project (0651-0011), Washington, D.C. 20503.

CONFORMS WITH FORM PTO-1595

01/13/2004 LMUELLER 00000073 161445 10688566

01 FC:8021 40.00 DA

700103997

ASSIGNMENT RECORDAL CVR SHEET (GROTON) TO PATENT (REV) PREVIOUS, 10/01

REEL: 015003 FRAME: 0785

PC25227A  
Joint Inventors (Pfizer - US Only)

**ASSIGNMENT**

For valuable consideration, the receipt and adequacy of which is hereby acknowledged we **Mohamed Mohamed Ali AWAD** of Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States of America, **Marc Jacques BAZIN, Frederic FERU** of Pfizer Global Research and Development, 3 a 9, rue de la Loge, B.P. 100, 94265 Fresnes, Cedex, France, **Steven Wayne GOLDSTEIN** Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States of America and **Cyrille Francois KUHN** of Pfizer Discovery Technology Center, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States of America, hereby sell, assign and transfer unto **WARNER-LAMBERT COMPANY LLC**, a limited liability company organised and existing under the laws of the State of Delaware, and having a place of business at 201 Tabor Road, Morris Plains, New Jersey 07950, United States of America, the entire right, title, and interest in and to our application for Letters Patent of the United States, executed the


Application no. 10/688,566 filed October 17, 2003  
entitled **QUINOLINE DERIVATIVES AS CRTH2 ANTAGONISTS** and our entire right, title and interest in the United States in and to all our inventions, whether joint or sole, disclosed in said application for Letters Patent, and in and to all United States patents granted on the foregoing inventions, and we hereby agree, whenever requested, to communicate to said assignee, its successors and assigns, any facts known to us respecting said inventions, to testify in any legal proceeding, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in the United States.

Signed and witnessed this <sup>5<sup>th</sup> &</sup> <sub>9<sup>th</sup></sub> day of *December* 2003  
at Groton, Connecticut, USA

  
Mohamed Mohamed Ali AWAD

  
Steven Wayne GOLDSTEIN

In the presence of:


  
(Witness)

Signed and witnessed this <sup>11<sup>th</sup></sup> day of *December* 2003  
~~at Fresnes, France~~

  
Marc Jacques BAZIN

  
Frederic FERU

In the presence of:

  
(Witness)

Signed and witnessed this \_\_\_\_\_ day of \_\_\_\_\_ 2003  
at Cambridge, MA, USA

\_\_\_\_\_  
Cyrille Francois KUHN

In the presence of:

\_\_\_\_\_  
(Witness)

PC25227A  
Joint Inventors (Pfizer - US Only)

**ASSIGNMENT**

For valuable consideration, the receipt and adequacy of which is hereby acknowledged we **Mohamed Mohamed Ali AWAD** of Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States of America, **Marc Jacques BAZIN, Frederic FERU** of Pfizer Global Research and Development, 3 a 9, rue de la Loge, B.P. 100, 94265 Fresnes, Cedex, France, **Steven Wayne GOLDSTEIN** Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States of America and **Cyrille Francois KUHN** of Pfizer Discovery Technology Center, 620 Memorial Drive, Cambridge, Massachusetts 02139, United States of America, hereby sell, assign and transfer unto **WARNER-LAMBERT COMPANY LLC**, a limited liability company organised and existing under the laws of the State of Delaware, and having a place of business at 201 Tabor Road, Morris Plains, New Jersey 07950, United States of America, the entire right, title, and interest in and to our application for Letters Patent of the United States, executed the

Application no. 10/688,566 filed October 17, 2003

entitled **QUINOLINE DERIVATIVES AS CRTH2 ANTAGONISTS** and our entire right, title and interest in the United States in and to all our inventions, whether joint or sole, disclosed in said application for Letters Patent, and in and to all United States patents granted on the foregoing inventions, and we hereby agree, whenever requested, to communicate to said assignee, its successors and assigns, any facts known to us respecting said inventions, to testify in any legal proceeding, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in the United States.

Signed and witnessed this \_\_\_\_\_ day of \_\_\_\_\_ 2003  
at Groton, Connecticut, USA

\_\_\_\_\_  
**Mohamed Mohamed Ali AWAD**

\_\_\_\_\_  
**Steven Wayne GOLDSTEIN**

In the presence of:

\_\_\_\_\_  
(Witness)

Signed and witnessed this \_\_\_\_\_ day of \_\_\_\_\_ 2003  
at Fresnes, France

\_\_\_\_\_  
**Marc Jacques BAZIN**

\_\_\_\_\_  
**Frederic FERU**

In the presence of:

\_\_\_\_\_  
(Witness)

Signed and witnessed this \_\_\_\_\_ day of December 2003  
at Cambridge, MA, USA

\_\_\_\_\_  
**Cyrille Francois KUHN**

In the presence of:

\_\_\_\_\_  
(Witness)